Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clascoterone cream 1% in acne vulgaris
NCT06425900Phase 4Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Jul 2024
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clascoterone in acne vulgaris, sponsored by Sun Pharma. Primary endpoint: Histologic Demonstration of Reduced Facial Sebaceous Gland Size at 12 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
clascoterone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06425900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425900.